GHTM

Global Health and Tropical Medicine

  • GHTM
    • Vision
    • Mission
    • Governance
    • Scientific Advisory Board
  • News
    • Outreach
    • Events
      • GHTM Sessions
      • Workshops
    • Articles
    • Jobs
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases and pathogens
      • IHC – Individual health care
    • Research in numbers
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
      • Completed Projects
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases and pathogens
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Technical / administrative support
  • Publications
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Education
    • Master Theses
    • PhD Theses
  • Services
  • Reports
    • GHTM
    • Scientific Advisory Board
    • FCT
Home / Publicações / Lack of evidence for the selection of E138 mutations by first-generation non-nucleoside reverse transcriptase inhibitors in patients infected with HIV-1 non-B subtypes

Lack of evidence for the selection of E138 mutations by first-generation non-nucleoside reverse transcriptase inhibitors in patients infected with HIV-1 non-B subtypes

  • Autores: Abecasis AB, Theys K, Van Laethem K
  • Ano de Publicação: 2015
  • Journal: AIDS
  • Link: https://insights.ovid.com/pubmed?pmid=25909833

Understanding the mechanisms and predictors of drug resistance development to HIV-1 antiretroviral therapy (ART) is a key challenge to further improve HIV-1 treatment strategies and prevent epidemic spread. The extensive genetic diversity characterizing the HIV-1 pandemic, classified into groups, subtypes and recombinants, has been shown to affect viral escape from drug-selective pressure and influence treatment decisions [1]. In previous issues of AIDS, Crawford and colleagues reported the selection of mutations E138A/G/K/Q upon treatment failure with first-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz (EFV) or nevirapine (NVP) in patients infected with subtypes A1, D and recombinant form A2D [2,3]. Amino acid substitutions at polymorphic position E138 in the reverse transcriptase enzyme recently acquired clinical relevance by their association with reduced in-vitro activity and in-vivo response to second-generation NNRTIs etravirine and rilpivirine [4–7]. Crawford et al.[2] reported their findings as unique given that, in their dataset, mutations at E138 were selected in non-B subtype viruses and upon treatment exposure with first-generation NNRTIs.

Share this:

  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to print (Opens in new window)

Events

LIDo: Fully-funded PhD scholarships in the UK

  The London Interdisciplinary Doctoral Programme (LIDo) brings together a group of … [Read More...]

VAX-TRUST: GHTM-IHMT hosted the seminar on strategies to tackle vaccine hesitancy

  Between 24th and 26th of October, the GHTM-IHMT-NOVA hosted a seminar to reflect on … [Read More...]

EuCARE will host the ‘Joint dialogue on preparedness’

The GHTM has the pleasure to announce that the meeting ‘Joint Dialogue on Preparedness’, organized … [Read More...]

4 Researchers from GHTM-IHMT-NOVA In the Stanford University Ranking of The 2% most cited Worldwide

  NOVA is growing not only in the list that counts citations over the course of a career, … [Read More...]

Call for PhD Studentships

The Institute of Hygiene and Tropical Medicine (IHMT), Universidade Nova de Lisboa (NOVA), through … [Read More...]

IHMT | GHTM – APPLICATIONS ARE OPEN!

IHMT | GHTM - Applications are open for three research vacancies:   One position - PhD … [Read More...]

About GHTM

GHTM is a R&D Center that brings together researchers from IHMT with a track record in Tropical Medicine and International/Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal
+351 213 652 600
+351 213 632 105

  • Facebook
  • YouTube

Subscribe Newsletter

  • How to get to GHTM/IHMT
  • GHTM Sessions
  • Research Groups
  • Cross-cutting issues
© Copyright 2023 IHMT-UNL Todos os Direitos Reservados.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    Project UID/Multi/04413/2013